Bronchopulmonary dysplasia · preterm infants with or at risk of respiratory distress syndrome
Inositol supplementation to preterm infants (repeat doses in any… showed no clear difference in bronchopulmonary dysplasia (at 36 to 38 weeks' PMA) compared with control (moderate certainty).
1 finding from 1 review
Bronchopulmonary dysplasia · preterm infants receiving nasal CPAP
Bubble showed no clear difference in bronchopulmonary dysplasia compared with ventilator or Infant Flow Driver nasal continuous positive airway… (low certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia · respiratory failure in preterm infants
Inhaled NO showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks ‐ Studies with entry… compared with control (high certainty).
2 findings from 1 review
Bronchopulmonary dysplasia or mortality ‐ not reported · preterm infants at risk of respiratory distress syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bronchopulmonary dysplasia · preterm infants at risk of respiratory distress syndrome
Surfactant treatment guided by rapid tests for surfactant deficiency showed no clear difference in bronchopulmonary dysplasia№ of participants: 562(3 RCTs) compared with surfactant therapy provided to preterm infants with respiratory… (low certainty).
1 finding from 1 review
RR 0.9 [0.61, 1.32]
Studies not reported
Low
Bronchopulmonary dysplasia at 36 weeks' postmenstrual age · preterm infants with respiratory distress for initial respiratory support
It is very uncertain whether early changes bronchopulmonary dysplasia at 36 weeks' postmenstrual age compared with late continuous positive airway pressure (CPAP) (very low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia · preterm infants receiving nasal CPAP
It is very uncertain whether mask changes bronchopulmonary dysplasia compared with prongs (very low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia · preterm infants
Enteral zinc supplementation showed no clear difference in bronchopulmonary dysplasia compared with no zinc supplementation (low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia · preterm infants < 37 weeks' gestational age requiring conventional mechanical ventilation for respiratory distress syndrome
Oxygen‐guided lung‐recruitment maneuver showed no clear difference in bronchopulmonary dysplasia compared with routine care (low certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia · preterm infants with or at risk of respiratory distress syndrome
Surfactant administration via laryngeal mask airway (S‐LMA) showed no clear difference in death or bronchopulmonary dysplasia compared with surfactant administration via endotracheal tube (ETT) with the… (low certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia · preterm infants with or at risk of respiratory distress syndrome
Surfactant administration via laryngeal mask airway (S‐LMA) showed no clear difference in death or bronchopulmonary dysplasia compared with no surfactant administration (low certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia · preterm infants with or at risk of respiratory distress syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bronchopulmonary dysplasia at 28 days · preterm infants
It is very uncertain whether prophylactic CPAP changes bronchopulmonary dysplasia at 28 days compared with very early CPAP (very low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia at 28 days · symptomatic patent ductus arteriosus in preterm infants
Indomethacin showed no clear difference in bronchopulmonary dysplasia at 28 days compared with placebo or control (low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · Parenterally fed preterm infants
MFS‐LE showed no clear difference in bronchopulmonary dysplasia/chronic lung disease compared with S‐LE (low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · Parenterally fed preterm infants
It is very uncertain whether MS‐LE changes bronchopulmonary dysplasia/chronic lung disease compared with S‐LE (very low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · Parenterally fed preterm infants
All fish oil containing LE showed no clear difference in bronchopulmonary dysplasia/chronic lung disease compared with S‐LE (low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · Parenterally fed preterm infants
It is very uncertain whether all alternative LE changes bronchopulmonary dysplasia/chronic lung disease compared with S‐LE (very low certainty).
Bronchopulmonary dysplasia/chronic lung disease · Parenterally fed preterm infants
MOFS‐LE showed no clear difference in bronchopulmonary dysplasia/chronic lung disease compared with S‐LE (low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia · symptomatic patent ductus arteriosus in preterm infants
Indomethacin showed no clear difference in bronchopulmonary dysplasia at 36 weeks' gestation compared with placebo or control (low certainty).
1 finding from 1 review